Clinical Trials Logo

Clinical Trial Summary

Both Neurofibromatosis type 1 (NF1) and Tuberous Sclerosis Complex (TSC) are highly heterogeneous diseases. Cognitive features seem to vary widely even between family members carrying the same mutation. This phenotypic variability is not well understood, but is generally assumed to be caused by modifier genes which regulate the affected pathways. However, recent studies brought forward an alternative explanation for the phenotypic variability. Post-mortem studies showed that second hit mutations causing loss of the second ('healthy') allele are more widespread than previously believed. These loss of heterozygosity (LOH) mutations cause bi-allelic loss of the disease-linked gene and are known to cause the gross of somatic features in both diseases (like neurofibromas and hamartomas). Hence, it could be the stochastic occurrence of second-hit mutations in the brain are the cause of the variable cognitive phenotypes.

To investigate to what extent these LOH mutations in the brain contribute to the phenotype and to what extent this variation is due to genetic modifiers factors is unknown. The investigators therefore propose to elucidate this variability by comparing the correlation of cognitive features of monozygotic twins with NF1 or TSC to healthy twins in the population. If modifier genes are the cause of the variability of cognitive features in NF1 and TSC the investigators expect that the variability in cognitive tests in monozygotic twins is the same as monozygotic twins in the healthy population. However, if the variability is caused by the occurrence of LOH mutations, the investigators expect to have a lower correlation in our monozygotic patients compared to the healthy twins.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT02436746
Study type Observational
Source Erasmus Medical Center
Contact Ype Elgersma, Prof.
Phone +31 10 7037739
Email y.elgersma@erasmusmc.nl
Status Recruiting
Phase N/A
Start date April 2015
Completion date April 2017

See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02687633 - Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex N/A
Completed NCT02201212 - Everolimus for Cancer With TSC1 or TSC2 Mutation Phase 2
Completed NCT01767779 - Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
Recruiting NCT05104983 - Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Phase 2
Recruiting NCT02098759 - Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex N/A
Recruiting NCT01730209 - Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase 2/Phase 3
Recruiting NCT03356769 - Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Phase 2
Recruiting NCT04987463 - Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Phase 2/Phase 3
Completed NCT05323370 - Lymphangioleiomyomatosis, a Study on Cathepsin K
Recruiting NCT06392009 - A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II Phase 1/Phase 2
Enrolling by invitation NCT05604170 - Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy Phase 3
Completed NCT03276195 - Studies in Patients With Tuberous Sclerosis Complex
Recruiting NCT05059327 - Basimglurant in Children, Adolescents, and Young Adults With TSC Phase 2
Completed NCT02061397 - Safety of Simvastatin in LAM and TSC Phase 1/Phase 2
Active, not recruiting NCT04112537 - Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Active, not recruiting NCT02962414 - Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Phase 3
Active, not recruiting NCT05495425 - Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC Phase 3
Active, not recruiting NCT05044819 - Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Phase 4
Completed NCT01929642 - Rapalogues for Autism Phenotype in TSC: A Feasibility Study Phase 2